Kythera Biopharmaceuticals Inc  

(Public, NASDAQ:KYTH)   Watch this stock  
Find more results for Keith F. Ball
35.07
-0.21 (-0.59%)
Real-time:   9:31AM EST
NASDAQ real-time data - Disclaimer
Currency in USD
Range 35.07 - 36.86
52 week 29.50 - 56.36
Open 35.15
Vol / Avg. 0.00/188,347.00
Mkt cap 795.23M
P/E     -
Div/yield     -
EPS -5.69
Shares 22.68M
Beta     -
Inst. own 104%
Mar 16, 2015
Q4 2014 KYTHERA Biopharmaceuticals Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Jan 12, 2015
KYTHERA Biopharmaceuticals Inc at JPMorgan Healthcare Conference - Webcast
Nov 20, 2014
KYTHERA Biopharmaceuticals Inc at Goldman Sachs US Emerging / SMID Cap Growth Conference
Nov 10, 2014
Q3 2014 KYTHERA Biopharmaceuticals Inc Earnings Call - Webcast
Nov 10, 2014
Q3 2014 KYTHERA Biopharmaceuticals Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -69.20% -38.51%
Return on average equity -100.29% -47.46%
Employees 64 -
CDP Score - -

Address

Suite 200 27200 West Agoura Road
CALABASAS, CA 91301
United States - Map
+1-818-5874500 (Phone)
+1-818-5874591 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

KYTHERA Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of prescription products for the aesthetic medicine market. The Company�s initial focus is on the facial aesthetics market. The Company�s product candidate, ATX-101, is an injectable drug in late-stage clinical development for the reduction of submental fat, which commonly presents as an undesirable double chin. The Company�s ATX-101 treatment contours the area under the chin by destroying fat cells while leaving surrounding tissue largely unaffected. The Company�s Phase II and Phase III studies have demonstrated that ATX-101, when injected subcutaneously into the target fat deposit, reduces the localized fat deposit while leaving the surrounding tissue largely unaffected. It is an attractive non-surgical solution for the reduction of submental fat.

Officers and directors

Keith R. Leonard Jr. President, Chief Executive Officer, Director
Age: 52
Bio & Compensation  - Reuters
John W. Smither Chief Financial Officer
Age: 61
Bio & Compensation  - Reuters
Jeffrey D. Webster Senior Vice President - Operations
Age: 52
Bio & Compensation  - Reuters
Keith L. Klein J.D. General Counsel
Age: 50
Bio & Compensation  - Reuters
Frederick Beddingfield III, M.D., Ph.D. Chief Medical Officer
Age: 49
Bio & Compensation  - Reuters
Hollings C. Renton III Director
Age: 64
Bio & Compensation  - Reuters
F. Michael Ball Independent Director
Age: 58
Bio & Compensation  - Reuters
Nathaniel E. David Ph.D. Independent Director
Age: 46
Bio & Compensation  - Reuters
Dennis M. Fenton Ph.D. Independent Director
Age: 62
Bio & Compensation  - Reuters
Francois Kress Independent Director
Age: 47
Bio & Compensation  - Reuters